Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 159 publications
Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: August 17, 2026
Erratum: Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 08, 2026
Metabolomic and lipidomic profiling reveals distinct subtypes of glioblastoma IDH-wildtype and shared metabolic features with astrocytoma IDH-mutant grade 4.
Journal: Neuro-oncology advances
Published: June 17, 2026
Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 03, 2026
Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 03, 2026
Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 09, 2026
Efficacy of Bioengineered PD-L1 siRNA for Immunotherapy Against Non-Small Cell Lung Cancer Cells.
Journal: Non-coding RNA
Published: April 03, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 26, 2026
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 20, 2026
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 13, 2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 19, 2026
Last Updated: 09/26/2026